HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies.
2015 was a record year for biopharma M&A with a worldwide transaction volume of $430 billion (including asset deals and announced transactions).
Deal volume of completed US transactions almost reached $200 billion (up from $90 billion in 2014). Deal volume in Europe dropped to $20 billion (from $50 billion in 2014). A record number of 21 US/European companies were sold for $1 billion or more (up from 14 such transactions in 2014 and 4 in 2013).
Trade sales of both private-equity and venture-backed companies reached record deal values.
In terms of exit multiples and absolute gains from biopharma trade sales, 2015 was probably the best ever “exit year” for venture investors on both sides of the Atlantic. Trade sales of oncology companies in 2015 generated over 40% of transaction volume and superior investor returns.
The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:
http://www.hbmpartners.com/en/industry-reports/pharma-biotech-report.php